CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

CADTH pan-Canadian Oncology Drug Review

pCODR RSS feed

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Olaparib (Lynparza) for Metastatic Castration-Resistant Prostate Cancer
(Open for Input on Submission until October 6, 2020)

Niraparib (Zejula) for First Line Ovarian Cancer
(Open for Input on Submission until October 5, 2020)

Avelumab (Bavencio) for Urothelial Carcinoma
(Open for Input on Submission until October 2, 2020)

Enzalutamide (Xtandi) for Metastatic Castration Sensitive Prostate Cancer
(Final Recommendation Issued as of September 23, 2020)

Niraparib (Zejula) for Ovarian Cancer
(Notification to Implement Issued as of September 21, 2020)

Decitabine-Cedazuridine (Inqovi) for Myelodysplastic Syndromes
(Pending Submission as of August 31, 2020)

Polatuzumab Vedotin (Polivy) for Diffuse Large B-Cell Lymphoma
(Pending Submission as of August 31, 2020)

Brigatinib (Alunbrig) for Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer
(Pending Submission as of September 1, 2020)

Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Non-Small Cell Lung Cancer BRAF V600 Mutation
(Pending Submission as of September 2, 2020)

Find a Drug Review